Our RESETTM clinical trials with CABA-201 (investigational CD19-CAR T cell therapy) in lupus, myositis, systemic sclerosis, myasthenia gravis, and pemphigus vulgaris are now recruiting.
| Date | Form | Description | XBRL | Pages | |
|---|---|---|---|---|---|
| 11/14/25 | SCHEDULE 13G/A | Statement of Beneficial Ownership by Certain Investors |
|
5 | |
| 11/14/25 | SCHEDULE 13G/A | Statement of Beneficial Ownership by Certain Investors |
|
9 | |
| 11/14/25 | SCHEDULE 13G/A | Statement of Beneficial Ownership by Certain Investors |
|
5 | |
| 11/10/25 | 10-Q | Quarterly report [Sections 13 or 15(d)] |
|
  |
114 |
| 11/10/25 | 8-K | Current report |
|
|
9 |
| 11/07/25 | SCHEDULE 13G/A | Statement of Beneficial Ownership by Certain Investors |
|
4 | |
| 11/07/25 | SCHEDULE 13G/A | Statement of Beneficial Ownership by Certain Investors |
|
4 | |
| 11/07/25 | SCHEDULE 13G/A | Statement of Beneficial Ownership by Certain Investors |
|
4 | |
| 11/05/25 | SCHEDULE 13G/A | Statement of Beneficial Ownership by Certain Investors |
|
4 | |
| 10/29/25 | 8-K | Current report |
|
|
56 |
